Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News
June 27th 2025

Understanding Patient and Caregiver Burdens in Acute Leukemia Treatment

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 11th 2025

Quality Improvement Project Enhances AML Genomic Testing Efficiency

June 4th 2025

ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges

Video Interviews
View All
July 1st 2025

Early SYRUS Data Highlight Safety, Efficacy of AZD0486 in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

June 29th 2025

Drivers of Cost Savings for Revumenib for Rare Acute Leukemias: Ivo Abraham, PhD, RN

June 28th 2025

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

June 26th 2025

Revumenib for Rare Acute Leukemias Is Cost-Neutral for Health Plans: Ivo Abraham, PhD, RN

June 24th 2025

Beat AML Master Trial Finds Strong Response With Triplet Therapy: Ashley Yocum, PhD

July 13th 2024

W-T7 Shows Encouraging Response Rate, Manageable Safety in Relapsed/Refractory T-ALL/LBL

More News

Stephen Strickland, MD, MSCI | Image credit: SCRI
May 13th 2025

Durability, Reduced Toxicity of CAR NK Therapy in AML May Aid Curative Treatment

Stephen Strickland, MD, MSCI Interview by Mary Caffrey
Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor natural killer (CAR NK) cell therapy. Toxicity with this therapy is lower than seen in many conventional CAR T-cell therapies.
CAR NK cells | Image credit: MD Anderson
May 12th 2025

For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone

Stephen Strickland, MD, MSCI Interview by Mary Caffrey
First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Elias Jabbour, MD | Image credit: MD Anderson
January 22nd 2025

MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL

Mary Caffrey Elias J. Jabbour, MD
Studies presented at ASH 2024 added to the understanding of real-world treatment and outcomes for patients with pediatric AML. | Image credit: LASZLO - stock.adobe.com
January 7th 2025

Studies Examine Real-World Pediatric AML Treatment and Outcomes

Kimberly Rath, PharmD
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients treated for pediatric acute myeloid leukemia (AML).
Jennifer Vaughn, MD, smiling during a zoom interview
December 26th 2024

The Balance of Managing Younger Patients With MPNs for Long-Term Treatment

Laura Joszt, MA
There are a number of considerations both in the short and long term to consider when making treatment decisions for younger patients with myeloproliferative neoplasms (MPNs).
Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD
A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
AML cells | Image Credit: © LASZLO - stock.adobe.com
December 17th 2024

Researchers Characterize Defining Feature of Pediatric AML Subtype

AJMC Contributor
Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.
Graphic with the words "The Top 5 ALL/AML Content in 2024" on a red background with health care icons along the top
December 16th 2024

Top 5 Most-Read ALL/AML Articles in 2024

Laura Joszt, MA
New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.
AML Acute Myeloid Leukemia | Image Credit: © momius-stock.adobe.com
December 7th 2024

Receiving ASCT After First CR May Improve Certain Outcomes in AML

AJMC Contributor
The meta-analysis found indications that autologous stem cell transplantation (ASCT) is associated with higher rates of disease-free survival and relapse-free survival, as well as lower rates of relapse compared with chemotherapy after patients achieved their first complete response (CR).
Nurse holding older woman's hands | Image credit: Cecilie Arcurs:peopleimages.com - stock.adobe.com
November 30th 2024

New CPX-351 Data Underscore Complexity of Treating AML in Older Patients 

Jared Kaltwasser
Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or complete response with incomplete hematologic recovery after one or two cycles of induction therapy with CPX-351.
Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com
November 29th 2024

Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines

Kyle Munz
With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
FDA Approval | image credit: gomixer - stock.adobe.com
November 26th 2024

FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

Kyle Munz
The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.
AML cells concept | image credit: sovova - stock.adobe.com
November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Kristi Rosa
Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.
Genes - CrazyJuke - stock.adobe.com
November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

Kimberly Rath, PharmD
Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).
FDA approval stamp | Image credit: BHM-stock.adobe.com
November 8th 2024

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

Laura Joszt, MA
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.
Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

Kimberly Rath, PharmD
Posttransplantation treatment with either tacrolimus or cyclosporine A results in favorable outcomes, but tacrolimus may be better at preventing severe graft-versus-host disease (GVHD), according to new study findings.
New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
AML | Image Credit: © Andrey - stock.adobe.com
October 30th 2024

After HMA Resistance in AML, a New Possible Therapy Option

Gayle Turim Dickstein
When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase called TOPORS may help.
Blood smear AML | image credit: Chansom Pantip - stock.adobe.com
October 20th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

AJMC Contributor
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Rash is a common side effect of an idarucibin and cytarabine induction intervention for AML | image credit: Kittiphan - stock.adobe.com
October 16th 2024

Researchers Identify Potential Predictors of Rash During AML Induction Therapy

AJMC Contributor
The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash.
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML | image credit: Matthieu - stock.adobe.com
October 16th 2024

Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML

Jared Kaltwasser
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.
AML cells | image credit: TheWaterMeloonProjec - stock.adobe.com
October 3rd 2024

New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+

Kimberly Rath, PharmD
Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
Research graphic | Image Credit: © marikova-stock.adobe.com
September 20th 2024

Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant

Kimberly Rath, PharmD
A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Acute myeloid leukemia | Image: St Jude Children's Research Center
September 19th 2024

Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes

Kyle Munz
Coverage from the Institute for Value-Based Medicine session at Ohio State University. This article will appear in the October issue of Evidence-Based Oncology.
Risk stratification in AML could benefit from mutational scoring | image credit: faraktinov - stock.adobe.com
September 17th 2024

Mutational Score May Improve Risk Stratification of Certain Patients With AML

AJMC Contributor
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption of a mutation score that accounts for certain gene mutations.
AML | Image Credit: © Dzmitry - stock.adobe.com
September 9th 2024

Key Biomarker Monitoring Improves Outcomes in ASCT Recipients With AML, MDS

Karen Jacobson-Sive
Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients with a baseline CD34 donor chimerism of less than 80%.
Enhanced image of leukemia | Image Credit: © freshidea - stock.adobe.com
September 6th 2024

Two Leukemia Stem Cell Subtypes Identified

Karen Jacobson-Sive
Researchers have discovered 2 leukemia stem cell subtypes with distinct epigenetic and transcriptional signatures.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo